CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Clinical trial NCT04271410 · UNKNOWN

Trial details

NCT number: NCT04271410
Sponsor: Chongqing Precision Biotech Co., Ltd
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia Lymphoma, Large B-Cell, Diffuse Leukemia, B-cell Lymphoma, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell

Start date: 2019-06-01
Primary completion: 2023-12-31
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.